Zimbabwe has rejected a major American health deal valued at $367m (£272m) spanning five years due to the United States' demand for sensitive data.
This rejection was revealed following a internal memorandum from December was disclosed, which showed President Emmerson Mnangagwa felt the deal was "lopsided".
An official spokesman later explained that the United States was demanding access to biological samples for research and commercial gain while was unwilling to share the resulting advantages from future vaccines.
"We will now turn to the challenging and unfortunate task of scaling back our health aid in Zimbabwe," stated US ambassador to Zimbabwe Pamela Tremont in a statement.
The US Embassy noted the US had donated over $1.9bn in health funding to Zimbabwe over the last two decades.
A medical body in Zimbabwe has called for more negotiations to secure a agreement agreeable to all parties so the country's vital HIV treatment initiative can proceed.
Wider Background
This development follows a similar case in neighbouring Kenya, where a court blocked a related health funding agreement after legal challenges were raised about the security of citizens' health data.
After returning to office recently, US President Donald Trump has slashed overseas assistance and closed the US Agency for International Development (USAID).
USAID had overseen aid for the American government, but Trump claimed its expenditure was "wasteful" and his administration was seeking direct bilateral agreements to enhance transparency and responsibility.
According to reports, Sixteen nations in Africa have to date agreed to these new agreements, constituting more than $18.3bn in new funding.
Specifics of the Declined Deal
The money for Zimbabwe would have gone towards "HIV/Aids treatment and prevention, tuberculosis, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"We believe this cooperation might have yielded immense benefits for Zimbabwean communities, particularly the 1.2 million men, women and children presently on antiretroviral therapy through US-supported initiatives," Tremont commented.
However, official spokesman Nick Mangwana maintained the proposed deal was "unequal".
"Zimbabwe was being asked to provide its biological resources and data for a long time, without any corresponding promise of benefiting from any scientific breakthroughs – such as new medicines or tests – that could result from that provided information," he stated.
"Put simply, our nation would supply the basic resources for scientific discovery with no assurance that the resulting innovations would be accessible to our citizens if a new health crisis emerge."
National Interest and Global Health
Mangwana further pointed out that the US's withdrawal from the World Health Organization (WHO) and its pursuit of bilateral deals were undermining systems already established through the global organization.
Mangwana cited its Pandemic Benefit-Sharing scheme created to deal with potential global health emergencies.
"This mechanism is designed to ensure that when a country contributes its data, the benefits – including vaccines and treatments – are shared equitably, not commercialised solely by those with the resources to create them."
These objections over the US deal "must not be interpreted as hostility towards the US," he added.
"We encourage ongoing discussions with our American counterparts on how future co-operation could be structured in a way that honours the sovereignty and dignity of each country."
Health Experts Reaction
A leading public health body stated it recognised the official position, but urged that negotiations need to persist since much of the nation's HIV programmes relied on foreign aid.
"Where technical issues arise, such as those involving information security or agreement terms, these can frequently be resolved via detailed discussion and mutually agreed protections," it added.
The halted deal highlights the ongoing debate between accepting much-needed foreign assistance and safeguarding national sovereignty in an increasingly data-driven world.